BioAge Labs (BIOA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.84, -9.53% vs the prior close of $5.35.
- Volume 867.08K shares, 1.2x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BIOA slides 9.5% to $4.84, a 52-week low, 5 down days in a row. Closed at $4.84, -9.53% vs the prior close of $5.35. Day range $4.81–$5.35, opened at $5.35.
BIOA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BIOA slides 9.5% to $4.84, a 52-week low, 5 down days in a row
- Closed at $4.84, -9.53% vs the prior close of $5.35. Day range $4.81–$5.35, opened at $5.35.
- Volume was 867.08K shares, 1.2x its 50-day average of 719.05K.
- Price is -42.6% vs its 50-day average ($8.43) and -70.4% vs its 200-day average ($16.33).
- 52-week range $4.81–$25.95; today's close sits at 0% of that range, 81.4% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — BIOA dips 1.3% to $5.35, a 6-month low, 4 down days in a row
- Closed at $5.35, -1.29% vs the prior close of $5.42. Day range $5.28–$5.50, opened at $5.48.
- Volume was 811.30K shares, 1.1x its 50-day average of 725.38K.
- Price is -37.5% vs its 50-day average ($8.56) and -67.3% vs its 200-day average ($16.38).
- 52-week range $5.04–$25.95; today's close sits at 1% of that range, 79.4% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — BIOA dips 2.7% to $5.42, a 6-month low, 3 down days in a row
- Closed at $5.42, -2.69% vs the prior close of $5.57. Day range $5.36–$5.58, opened at $5.49.
- Volume was 614.90K shares, 0.8x its 50-day average of 760.48K.
- Price is -37.5% vs its 50-day average ($8.67) and -67.0% vs its 200-day average ($16.42).
- 52-week range $5.04–$25.95; today's close sits at 2% of that range, 79.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BIOA slides 6.2% to $5.57, a 6-month low
- Closed at $5.57, -6.23% vs the prior close of $5.94. Day range $5.54–$5.90, opened at $5.90.
- Volume was 638.50K shares, 0.8x its 50-day average of 818.39K.
- Price is -36.6% vs its 50-day average ($8.78) and -66.2% vs its 200-day average ($16.46).
- 52-week range $5.04–$25.95; today's close sits at 3% of that range, 78.5% below the 52-week high.
Oct 12, 2026 — BIOA slides 6.3% to $5.94, a 6-month low
- Closed at $5.94, -6.31% vs the prior close of $6.34. Day range $5.88–$6.30, opened at $6.24.
- Volume was 482.00K shares, 0.5x its 50-day average of 1.01M — lighter than usual.
- Price is -33.2% vs its 50-day average ($8.89) and -64.0% vs its 200-day average ($16.51).
- 52-week range $5.04–$25.95; today's close sits at 4% of that range, 77.1% below the 52-week high.
Oct 9, 2026 — BIOA rises 2.1% to $6.34
- Closed at $6.34, +2.09% vs the prior close of $6.21. Day range $6.14–$6.47, opened at $6.21.
- Volume was 667.30K shares, 0.7x its 50-day average of 1.01M.
- Price is -29.2% vs its 50-day average ($8.95) and -61.7% vs its 200-day average ($16.54).
- 52-week range $5.04–$25.95; today's close sits at 6% of that range, 75.6% below the 52-week high.
Oct 8, 2026 — BIOA dips 0.8% to $6.21, a 6-month low, 8 down days in a row
- Closed at $6.21, -0.80% vs the prior close of $6.26. Day range $5.99–$6.26, opened at $6.17.
- Volume was 906.90K shares, 0.9x its 50-day average of 1.01M.
- Price is -33.4% vs its 50-day average ($9.32) and -62.5% vs its 200-day average ($16.58).
- 52-week range $5.04–$25.95; today's close sits at 6% of that range, 76.1% below the 52-week high.
- That makes 8 straight losses.
Oct 7, 2026 — BIOA dips 0.5% to $6.26, a 6-month low, 7 down days in a row
- Closed at $6.26, -0.48% vs the prior close of $6.29. Day range $6.17–$6.68, opened at $6.23.
- Volume was 799.50K shares, 0.8x its 50-day average of 1.01M.
- Price is -35.1% vs its 50-day average ($9.64) and -62.3% vs its 200-day average ($16.61).
- 52-week range $5.04–$25.95; today's close sits at 6% of that range, 75.9% below the 52-week high.
- That makes 7 straight losses.
Oct 6, 2026 — BIOA dips 1.1% to $6.29, a 6-month low on 3.4x normal volume
- Closed at $6.29, -1.10% vs the prior close of $6.36. Day range $6.00–$6.45, opened at $6.44.
- Volume was 3.25M shares, 3.4x its 50-day average of 951.90K — unusually heavy trading.
- Price is -36.8% vs its 50-day average ($9.95) and -62.2% vs its 200-day average ($16.64).
- 52-week range $5.04–$25.95; today's close sits at 6% of that range, 75.8% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — BIOA slides 3.8% to $6.36, a 6-month low, 5 down days in a row
- Closed at $6.36, -3.78% vs the prior close of $6.61. Day range $6.25–$6.65, opened at $6.65.
- Volume was 781.20K shares, 0.8x its 50-day average of 956.89K.
- Price is -37.9% vs its 50-day average ($10.25) and -61.9% vs its 200-day average ($16.67).
- 52-week range $5.04–$25.95; today's close sits at 6% of that range, 75.5% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — BIOA dips 2.9% to $6.61, a 6-month low, 4 down days in a row
- Closed at $6.61, -2.94% vs the prior close of $6.81. Day range $6.47–$6.92, opened at $6.92.
- Volume was 869.60K shares, 0.9x its 50-day average of 947.83K.
- Price is -37.4% vs its 50-day average ($10.55) and -60.4% vs its 200-day average ($16.71).
- 52-week range $5.04–$25.95; today's close sits at 8% of that range, 74.5% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
BIOA latest news & SEC filings
Every SEC filing by or about BIOA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $2.45M (prior year $2.41M) (+1.6% vs Jun 30, 2025)
- Net income: -$26.10M (prior year -$21.56M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.58 (prior year -$0.60) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Barton Shane sold 20,216 shares at $25.19 (≈$509.24K) on Jun 30, 2026
- Barton Shane sold 20,216 shares at $25.19 (≈$509.24K) on Jun 30, 2026
- Barton Shane sold 20,216 shares at $25.19 (≈$509.24K) on Jun 30, 2026
- Barton Shane sold 20,216 shares at $25.19 (≈$509.24K) on Jun 30, 2026
- Barton Shane sold 42,350 shares at $25.21 (≈$1.07M) on Jun 29, 2026
- Barton Shane sold 42,350 shares at $25.21 (≈$1.07M) on Jun 29, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Things to know before you trade BIOA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 24, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.34% (largest 9.5%). That is a volatile stock.
- Liquidity: about 868.77K shares (≈$4.20M) trade per day on average.
- 52-week position: $4.84 vs a range of $4.81–$25.95 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Shane Barton sold 20,216 shares on Jun 30, 2026.
- Latest filings: 8-K Oct 2, 2026; 10-Q Aug 5, 2026; 8-K Aug 5, 2026.
- Share count: 45.90M shares outstanding (Jul 31, 2026), +28.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BIOA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 5.35 | 5.35 | 4.81 | 4.84 | 867.08K |
| Oct 15, 2026 | 5.48 | 5.50 | 5.28 | 5.35 | 811.30K |
| Oct 14, 2026 | 5.49 | 5.58 | 5.36 | 5.42 | 614.90K |
| Oct 13, 2026 | 5.90 | 5.90 | 5.54 | 5.57 | 638.50K |
| Oct 12, 2026 | 6.24 | 6.30 | 5.88 | 5.94 | 482.00K |
| Oct 9, 2026 | 6.21 | 6.47 | 6.14 | 6.34 | 667.30K |
| Oct 8, 2026 | 6.17 | 6.26 | 5.99 | 6.21 | 906.90K |
| Oct 7, 2026 | 6.23 | 6.68 | 6.17 | 6.26 | 799.50K |
| Oct 6, 2026 | 6.44 | 6.45 | 6.00 | 6.29 | 3.25M |
| Oct 5, 2026 | 6.65 | 6.65 | 6.25 | 6.36 | 781.20K |
| Oct 2, 2026 | 6.92 | 6.92 | 6.47 | 6.61 | 869.60K |
| Oct 1, 2026 | 7.06 | 7.17 | 6.70 | 6.81 | 591.10K |
| Sep 30, 2026 | 7.20 | 7.26 | 6.97 | 7.09 | 755.20K |
| Sep 29, 2026 | 7.19 | 7.27 | 7.07 | 7.14 | 424.90K |
| Sep 28, 2026 | 7.11 | 7.43 | 6.96 | 7.18 | 800.10K |
| Sep 25, 2026 | 7.26 | 7.30 | 7.03 | 7.05 | 630.30K |
| Sep 24, 2026 | 7.79 | 7.88 | 7.19 | 7.21 | 1.01M |
| Sep 23, 2026 | 8.43 | 8.49 | 7.68 | 7.89 | 618.50K |
| Sep 22, 2026 | 8.20 | 8.53 | 8.11 | 8.46 | 1.07M |
| Sep 21, 2026 | 8.07 | 8.10 | 7.73 | 8.09 | 787.00K |
About BioAge Labs
BioAge Labs (BIOA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in EMERYVILLE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1709941.
BIOA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael H. Davidson | Director | Jun 12, 2026 |
| Patrick G Enright | Director | Jun 12, 2026 |
| Kristen Fortney | Chief Executive Officer | Feb 19, 2026 |
| Jean Pierre Garnier | Director | Jun 12, 2026 |
| James Healy | Director | Jun 12, 2026 |
| Rekha Hemrajani | Director | Jun 12, 2026 |
| Eric Morgen | Chief Operating Officer | Feb 19, 2026 |
| Vijay Satyanand Pande | Director | Jun 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Shane Barton | Principal Accounting Officer | Jul 1, 2026 |
| Kristen Fortney | Chief Executive Officer | Feb 19, 2026 |
| Dov A Md Goldstein | Chief Financial Officer | Apr 24, 2026 |
| Eric Morgen | Chief Operating Officer | Feb 19, 2026 |
| Paul D Rubin | Chief Medical Officer | Apr 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 30, 2026 | Shane Barton | Sale | 20,216 | $25.19 |
| Jun 30, 2026 | Shane Barton | Sale | 20,216 | $25.19 |
| Jun 30, 2026 | Shane Barton | Sale | 20,216 | $25.19 |
| Jun 30, 2026 | Shane Barton | Sale | 20,216 | $25.19 |
| Jun 29, 2026 | Shane Barton | Sale | 42,350 | $25.21 |
| Jun 29, 2026 | Shane Barton | Sale | 42,350 | $25.21 |
| Jun 29, 2026 | Shane Barton | Sale | 42,350 | $25.21 |
| Jun 29, 2026 | Shane Barton | Sale | 42,350 | $25.21 |
| Apr 1, 2026 | Paul D Rubin | Sale | 8,820 | $17.81 |
| Apr 1, 2026 | Paul D Rubin | Sale | 8,820 | $17.81 |
| Apr 1, 2026 | Paul D Rubin | Sale | 8,820 | $17.81 |
| Apr 1, 2026 | Paul D Rubin | Sale | 8,820 | $17.81 |
| Mar 2, 2026 | Paul D Rubin | Sale | 7,433 | $20.30 |
| Mar 2, 2026 | Paul D Rubin | Sale | 7,433 | $20.30 |
| Mar 2, 2026 | Paul D Rubin | Sale | 7,433 | $20.30 |
BIOA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $8.99M | $-80.61M | -2.24 | $-81.63M |
| Dec 31, 2024 | $0 | $-71.11M | -6.63 | $-51.52M |
| Dec 31, 2023 | — | $-63.85M | -38.17 | $-37.36M |
Latest balance sheet: total assets $396.93M, total liabilities $22.02M, cash $73.96M (as of Jun 30, 2026).
BIOA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $10.98 |
| May 8, 2026 | 8-K Item 2.02 (results) | $17.99 |
| Mar 24, 2026 | 8-K Item 2.02 (results) | $16.11 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.47 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $4.33 |
| May 6, 2025 | 8-K Item 2.02 (results) | $3.95 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $4.38 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $20.62 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BIOA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.